Clinical Trial

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Study acronym: BaseTIL-02L
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-06; most recent amendment 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT06455917
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
Enrollment 30 participants
Start Date 2025-01-22
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-19